Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis

Thorax

Volumn 70, Issue 1, 2015, Pages 48-56

  DePianto, Daryle J ^a   Chandriani, Sanjay ^a,b   Abbas, Alexander R ^a   Jia, Guiquan ^a   N'Diaye, Elsa N ^a   Caplazi, Patrick ^a   Kauder, Steven E ^a   Biswas, Sabyasachi ^a   Karnik, Satyajit K ^a,c   Ha, Connie ^a   Modrusan, Zora ^a   Matthay, Michael A ^d   Kukreja, Jasleen ^d   Collard, Harold R ^d   Egen, Jackson G ^a   Wolters, Paul J ^d   Arron, Joseph R ^a  

^a GENENTECH INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c GILEAD SCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL13 CHEMOKINE; STROMELYSIN; CXCL13 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; FIBROSING ALVEOLITIS; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROGNOSIS; PROTEIN LOCALIZATION; SURVIVAL TIME; TISSUE CHARACTERIZATION; B LYMPHOCYTE; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; LUNG; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CHEMOKINE CXCL13; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84919768376     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-204596     Document Type: Article

References (38)

1. Adkins JM, Collard HR. Idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2012;33:433-9.
2. Ley B, Collard HR. Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;185:6-7.
3. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med 2012;136:591-600.
4. Cavazza A, Rossi G, Carbonelli C, et al. The role of histology in idiopathic pulmonary fibrosis: an update. Respir Med 2010;104(Suppl 1):S11-22.
5. Raghu G, Collard HR, Egan JJ, et al. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
6. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167-75.
7. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-7.
8. Yang IV, Coldren CD, Leach SM, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 2013.
9. Plantier L, Crestani B, Wert SE, et al. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax 2011;66:651-7.
10. Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest 2002;82:1335-45.
11. Seibold MA, Smith RW, Urbanek C, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PloS ONE 2013;8:e58658.
12. Nuovo GJ, Hagood JS, Magro CM, et al. The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol 2012;25:416-33.
13. Todd NW, Scheraga RG, Galvin JR, et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res 2013;6:63-70.
14. Vuga LJ, Tedrow JR, Pandit KV, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;189:966-74.
15. Mamehara A, Sugimoto T, Sugiyama D, et al. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci 2010;56:E98-107.
16. Rosengren S, Wei N, Kalunian KC, et al. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:603-10.
17. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008;40:1334-47.
18. Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46.
19. Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol 2011;179:1733-45.
20. Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-61.
21. Mura M, Anraku M, Yun Z, et al. Gene expression profi ling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. Chest 2012;141:661-73.
22. Kimura M, Taniguchi H, Kondoh Y, et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013;85:456-63.
23. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52.
24. Bringardner BD, Baran CP, Eubank TD, et al. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 2008;10:287-301.
25. Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000;406:309-14.
26. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
27. Litsiou E, Semitekolou M, Galani IE, et al. CXCL13 Production in B cells via toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:1194-202.
28. Bracke KR, Verhamme FM, Seys LJ, et al. Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and COPD. Am J Respir Crit Care Med 2013;188:343-55.
29. Meeuwisse CM, van der Linden MP, Rullmann TA, et al. Identi fication of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 2011;63:1265-73.
30. Taille C, Grootenboer-Mignot S, Boursier C, et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:759-66.
31. Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013;187:768-75.
32. Xue J, Kass DJ, Bon J, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol 2013;191:2089-95.
33. Lee JS, Kim EJ, Lynch KL, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med 2013;107:249-55.
34. McGrath EE, Millar AB. Hot off the breath: triple therapy for idiopathic pulmonary fibrosis - hear the PANTHER roar. Thorax 2012;67:97-8.
35. Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2142-3.
36. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-91.
37. Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:97-103.
38. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008;246:935-40.